Lilly’s Verzenio just misses the mark on overall survival in PhIII breast cancer study
Eli Lilly’s CDK4/6 inhibitor Verzenio barely missed the overall survival endpoint in a Phase III clinical trial for advanced breast cancer.
In the MONARCH 3 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.